Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Ocoxin-Viusid in the Prevention of Acute Toxicity by Chemotherapy in Patients With Breast Cancer. Phase II Clinical Trial

NCT03576521 is registered in ClinicalTrials.gov with Catalysis SL as lead sponsor.

NCT NCT03576521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03576521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Ocoxin-Viusid in the Prevention of Acute Toxicity by Chemotherapy in Patients With Breast Cancer. Phase II Clinical Trial
Lead sponsor
Catalysis SL
Phase
Phase 2
Overall status
Completed
Start date
May 13, 2015
Completion date
February 19, 2018
Enrollment
120 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adriamycin toxicity, breast cancer, breast carcinoma, cyclosporine toxicity